Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
NCT04203316
Recruiting
This phase II trial studies the side effects of enasidenib and sees how well it works in treating pediatric patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the growth of cancer cells by blocking the mutated IDH2 protein, which is needed for leukemia cell growth.
Gender:
ALL
Ages:
Between 24 months and 21 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +27 locations
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates
Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment
NCT04715984
Recruiting
The goal of this study is to learn more about the brain activity underlying Parkinson's disease cognitive impairment. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of Parkinson's disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease
Register for Updates
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
NCT05227937
Recruiting
The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation of the bladder). Participating in this study will allow the patient to treat their urinary tract infection (UTI) with a single intramuscular (IM (into the arm)) or intravenous (IV (into the vein)) shot of amikacin, rather than having to go to the pharmacy to pick up a prescription for antibiotics, an... Read More
Gender:
FEMALE
Ages:
Between 14 years and 110 years
Trial Updated:
03/18/2025
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Urinary Tract Infections
Register for Updates
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: USA Mitchell Cancer Institute, Mobile, Alabama +274 locations
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies
NCT05682378
Recruiting
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 or ORION-13 studies.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/18/2025
Locations: Excel Medical Clinical Trials LLC, Boca Raton, Florida +50 locations
Conditions: Heterozygous or Homozygous Familial Hypercholesterolemia
Register for Updates
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
NCT06026371
Recruiting
This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation involves receiving processed fecal material orally after allogeneic HCT in order to establish a healthy gut microbiota. Gut microbiota undergoes major alterations during allogeneic HCT because of antibiotic exposures, n... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Pedi-Cap CO2 Detector for Face-mask Ventilation in the Delivery Room
NCT06258187
Recruiting
The goal of this study is to determine if using a Pedi-Cap (a type of colorimetric carbon dioxide detector) during face mask ventilation (PPV) for newborn infants in the delivery room will lower the time of PPV needed. A group of nurses, doctors, and respiratory therapists, called the neonatal resuscitation team, will either use or not use the Pedi-Cap during face mask PPV for infants born at ≥30 weeks' gestation. A randomization generator will assign each month to either use the Pedi-Cap or no... Read More
Gender:
ALL
Ages:
30 weeks and above
Trial Updated:
03/18/2025
Locations: Parkland Health, Dallas, Texas
Conditions: Neonatal Resuscitation, Neonatal Disease
Register for Updates
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/18/2025
Locations: Local Institution - 0130, Sacramento, California +14 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +13 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Register for Updates
Comparative Clinical Trial: Manual Therapy with and Without Radial Extracorporeal Shockwave Therapy to Treat Acute Low Back Pain
NCT06852898
Recruiting
The goal of this clinical trial is to learn if the addition of radial pulse therapy to chiropractic care will help adult patients recover faster to an acute bout of low back pain. Radial pulse therapy is the application of acoustic waves that passes through the skin to tissues and cells in the body. The main questions that the clinical trial aims to answer are: * Does the addition of radial pulse therapy to chiropractic care result in better or earlier reduction in pain intensity? * Does the ad... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/18/2025
Locations: Seneca Falls Health Center at Northeast College of Health Sciences, Seneca Falls, New York
Conditions: Acute Lower Back Pain
Register for Updates
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
NCT04282187
Recruiting
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ruxolitinib, fedratinib, and pacritinib may stop the growth of tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Register for Updates
Mechanisms Underlying Individual Variations of Taste and Smell in Obesity
NCT04714892
Recruiting
Background: Changes to the sense of taste or smell can change eating behavior. This may contribute to obesity. Researchers want to see how taste and smell perceptions that affect food choices may differ between people with obesity and without obesity. Objective: To understand the role that senses of taste and smell play in food intake. Eligibility: Adults ages 18-65 with obesity and without obesity Design: Participants will be screened with a medical history and physical exam. They will h... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Obesity
Register for Updates